UNITED STATES

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): July 27, 2023

Kyndryl Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 001-40853 (Commission File Number) 86-1185492 (I.R.S. Employer Identification No.)

One Vanderbilt Avenue, 15th Floor New York, New York 10017 (Address of principal executive offices, and Zip Code)

212-896-2098 (Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | | | |
|---|----------------------|--|--|
| □ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) □ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) □ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) □ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | | | |
| Securities registered pursuant to Section 12(b) of the Act: | | | |
| Title of each class Common stock, par value \$0.01 per share | Trading symbol(s) KD | Name of each exchange on which registered New York Stock Exchange | |
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | | | |
| Emerging growth company \square | | | |
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | | | |
| | | | |
| | | | |

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(e) On July 27, 2023, Kyndryl Holdings, Inc. (the "Company") held its annual meeting of stockholders (the "Annual Meeting") at which the Company's stockholders approved the amendment and restatement of the Amended and Restated Kyndryl 2021 Long-Term Performance Plan (the "Amended Plan"), as described below. Also on July 27, 2023, the Compensation and Human Capital Committee of the Board of Directors of the Company (the "Compensation and Human Capital Committee") approved an amendment to the Kyndryl Executive Severance Plan and Executive Retirement Policy (the "Severance Plan"), as described below.

Amendment and Restatement of the Amended and Restated Kyndryl 2021 Long-Term Performance Plan ("Amended Plan")

At the Annual Meeting, the Company's stockholders approved the amendment and restatement of the Amended Plan, which increased the number of shares of the Company's common stock, par value \$0.01 per share, issuable under the Amended Plan by 17,000,000 shares. The material features of the Amended Plan, as amended and restated, are described in the section entitled "Proposal 3—Approval of the Amendment and Restatement of the Amended and Restated Kyndryl 2021 Long-Term Performance Plan" on pages 80 through 92 of the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on June 14, 2023 (the "2023 Proxy Statement") in connection with the Annual Meeting, which pages are incorporated herein by reference. The Amended Plan, as so amended and restated, is filed as Exhibit 10.1 hereto and incorporated herein by reference.

Amendments to the Severance Plan

Each of Martin Schroeter, the Company's Chairman and Chief Executive Officer, David Wyshner, the Company's Chief Financial Officer, Elly Keinan, the Company's Group President, Maryjo Charbonnier, the Company's Chief Human Resources Officer and Edward Sebold, the Company's General Counsel and Secretary (together, the "Named Executive Officers"), in addition to certain other senior executives of the Company, is eligible to participate in the Severance Plan. The amendment to the Severance Plan, approved by the Compensation and Human Capital Committee on July 27, 2023, gives the Vice President, Total Rewards of the Company ("Plan Administrator") the ability to waive the noncompete and customer nonsolicit requirements in the Plan where such requirements are prohibited in the United States.

Under the Severance Plan, each of the Named Executive Officers, in addition to certain other senior executives under the Long-Term Performance Plan ("Eligible Retirement Benefit Recipients"), may be eligible for continued equity award vesting upon termination from the Company. The amendment to the Severance Plan, approved by the Compensation and Human Capital Committee on July 27, 2023, adds a requirement that the Eligible Retirement Benefit Recipients must have completed one year of active service with the Company measured from the equity award grant date for such outstanding restricted stock units to be eligible for continued vesting following termination of employment in their outstanding units issued under the Amended Plan.

The amendments to the Severance Plan are filed as Exhibit 10.2 hereto and incorporated herein by reference.

Item 5.07 Submission of Matters to a Vote of Security Holders

At the Annual Meeting on July 27, 2023, the Company's stockholders: (1) elected the persons listed below to serve as directors; (2) approved, on an advisory basis, the compensation of the Company's named executive officers; (3) approved the amendment and restatement of the Amended and Restated Kyndryl 2021 Long-Term Performance Plan; and (4) ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2024. Each of these proposals is described in greater detail in the 2023 Proxy Statement. Set forth below are the voting results for these proposals.

Proposal 1—Election of Directors

Each director nominee received the support of at least 97% of the votes cast:

| Name | Votes For | Votes Against | Abstentions | Broker Non-Votes |
|-----------------------|-------------|---------------|-------------|-------------------------|
| John D. Harris II | 139,188,743 | 3,722,905 | 293,271 | 39,679,269 |
| Jana Schreuder | 140,331,843 | 2,592,852 | 280,224 | 39,679,269 |
| Howard I. Ungerleider | 140,685,278 | 2,224,861 | 294,780 | 39,679,269 |

Proposal 2—Advisory Vote to Approve Executive Compensation

88% of the votes present and entitled to vote approved the compensation of the Company's named executive officers:

| Votes For | Votes Against | Abstentions | Broker Non-Votes |
|-------------|---------------|-------------|-------------------------|
| 126.290.024 | 16.242.130 | 672,765 | 39.679.269 |

<u>Proposal 3—Approval of Amendment and Restatement of the Amended and Restated Kyndryl 2021 Long-Term Performance Plan ("Amended Plan").</u>

93% of the votes present and entitled to vote approved the amendment and restatement of the Amended and Restated Kyndryl 2021 Long-Term Performance Plan

| Votes For | Votes Against | Abstentions | Broker Non-Votes |
|-------------|---------------|-------------|-------------------------|
| 133,206,210 | 9,345,158 | 653,551 | 39,679,269 |

Proposal 4—Ratification of the Appointment of the Independent Registered Public Accounting Firm

99% of the votes present and entitled to vote ratified the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2024:

| Votes For | Votes Against | Abstentions | Broker Non-Votes |
|-------------|---------------|-------------|-------------------------|
| 181,703,319 | 811,632 | 369,237 | 0 |

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

| Exhibit No. | <u>Description</u> |
|-------------|---|
| <u>10.1</u> | Amended and Restated Kyndryl 2021 Long-Term Performance Plan (incorporated by reference to Exhibit 4.3 to the Company's |
| | Registration Statement on Form S-8 filed on July 31, 2023) |
| <u>10.2</u> | Amendment to the Kyndryl Executive Severance Plan and Executive Retirement Policy |
| 104 | Cover Page Interactive Data File (embedded in the Inline XBRL document) |
| | |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 31, 2023

KYNDRYL HOLDINGS, INC.

By: /s/ Evan Barth

Name: Evan Barth

Title: Vice President, Assistant General Counsel and

Assistant Corporate Secretary

Amendment 2 to the Kyndryl Executive Severance Plan and Executive Retirement Policy

The following amendments to the Kyndryl Executive Severance Plan and Executive Retirement Policy are effective for terminations of employment occurring on or after July 27, 2023.

1. Article 3 ("Severance Benefits") is amended by replacing the existing text under the heading "Amount of Severance Benefits" and immediately prior to the subheading "Calculation of Incentive Pay Amounts" with the following:

An Eligible Executive who has a Termination Without Cause after reaching age 55 and completing 10 years of service with Kyndryl (including, for this purpose, service with IBM for individuals whose employment was transferred from IBM to Kyndryl in connection with Kyndryl's spin-off from IBM as an independent publicly traded company) will also be eligible for continued vesting following termination of employment in the Eligible Executive's outstanding restricted stock units or cash awards issued under the Long-Term Performance Plan. The Eligible Executive must have completed one year of service with Kyndryl measured from the equity award grant date for such outstanding restricted stock units or cash awards to be eligible for continued vesting. This continued vesting is part of the Severance Benefits under the Plan and subject to signing and not revoking a confidential separation agreement as required under the Plan that also includes, except to the extent waived by Kyndryl for retirees outside the United States or where waiver is required by local law for retirees in the United States (in writing by the Plan Administrator), a two-year non-competition commitment as required under Kyndryl's Executive Retirement Policy.

2. Appendix ("Executive Retirement Policy") is amended by replacing the existing text of the second paragraph with the following. All subsequent bullet points under the second paragraph shall remain unchanged unless otherwise indicated in this Amendment 2:

Under the Executive Retirement Policy, if you are an Eligible Executive or otherwise a recipient of an Award under the Long-Term Performance Plan, you may be eligible for continued equity award vesting upon your termination from Kyndryl. You must have completed one year of active service with Kyndryl measured from the equity award grant date for such outstanding restricted stock units or cash awards to be eligible for continued vesting. You are eligible to continue to vest in your eligible outstanding restricted stock units or cash awards under the Long-Term Performance Plan following your termination of employment with Kyndryl if you meet all of the following requirements:

- 3. Appendix ("Executive Retirement Policy") is further amended by replacing the existing text of the second bullet point with the following:
 - · You terminate employment with Kyndryl after reaching age 55 and completing 10 years of service with Kyndryl (including, for this purpose, service with IBM for individuals whose employment was transferred from IBM to Kyndryl in connection with Kyndryl's spin-off from IBM as an independent publicly traded company);
- 4. Appendix ("Executive Retirement Policy") is further amended by replacing the existing text of the final bullet point with the following:
 - You sign and do not revoke an agreement and general release that will include, among other things, a release of any and all claims that you may have against Kyndryl, all of its affiliates and subsidiaries, and any of their employees, directors, or agents; confidentiality and trade secret commitments; a non-solicitation of Company employees for two years, and, except to the extent waived by Kyndryl for retirees outside the United States or where waiver is required by local law for retirees in the United States (in writing by the Plan Administrator for the Executive Severance Plan), a two-year non-competition commitment and a two-year non-solicitation of Company clients.